Cognitive functions in prepsychotic patients

Bartók, Enikő; Berecz, Roland; Glaub, T.; Degrell, I

doi:10.1016/j.pnpbp.2005.01.008

Cited by 60 publications

(43 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[24][25][26] In addition, early detection may shorten the overtly psychotic period, help establish good therapeutic alliance, and improve quality of life and long-term outcome by minimizing severity and disability. 24,27,28 Finally, such paradigms allow the prospective study of the transition process.…”

Section: The Importance Of Predictionmentioning

confidence: 99%

See 1 more Smart Citation

Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis

Brewer

Wood

Phillips

et al. 2005

Schizophrenia Bulletin

227

166

View full text Add to dashboard Cite

Section: The Importance Of Predictionmentioning

confidence: 99%

“…Bartok and colleagues 24 assessed young Hungarian adults referred to an outpatient clinic of the Department of Psychiatry at the University of Debrecen. They were referred for secondary care by general practitioners after help-seeking for nonspecific emotional or behavioral abnormalities.…”

Section: University Of Debrecenmentioning

confidence: 99%

Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis

Brewer

Wood

Phillips

et al. 2005

Schizophrenia Bulletin

227

166

View full text Add to dashboard Cite

“…These impairments are evident prior to other clinical aspects of the disease, 2 are lifelong, 3 and are accompanied by unfavorable outcomes in education, work, and social relationships. 1,4 Research and development activity to identify agents that improve cognitive functioning in this population has recently intensified.…”

Section: Introductionmentioning

confidence: 99%

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Haig

Bain

Robieson

et al. 2014

Schizophrenia Bulletin

View full text Add to dashboard Cite

Introduction: ABT-288 is a highly potent histamine-3 receptor antagonist that has demonstrated pro-cognitive effects in preclinical models relevant to schizophrenia. This study evaluated the efficacy and safety of two doses of ABT-288 in the treatment of cognitive impairment associated with schizophrenia. Methods: A randomized, double-blind, placebo-controlled, parallel-group 12-week study was conducted at 23 centers in the United States. Clinically stable subjects with schizophrenia were randomized in an equal ratio to ABT-288 10 mg, ABT-288 25 mg, or placebo once daily while continuing their antipsychotic regimen. The primary efficacy measure was the change from baseline to day 84 evaluation on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) composite score vs placebo. Secondary measures included cognitive functioning and psychiatric scales. Safety assessments and sparse pharmacokinetic sampling were also conducted. Results: A total of 214 subjects were randomized. The mean baseline MCCB composite score was 28.4. Approximately 80% of subjects completed the study. The MCCB composite score mean change from baseline to day 84 was numerically worse for both the 10 mg (1.90, P = .618) and 25 mg (0.64, P = .946) doses of ABT-288 vs placebo (2.19). Results from the secondary measures were consistent with the primary analysis. Subjects' schizophrenia symptoms remained stable throughout the study as evidenced by stable Positive and Negative Syndrome Scale scores. Overall, study medication was tolerated; however, an increased incidence of psychosis-related and sleep-related adverse events was associated with ABT-288. Discussion: Neither dose of ABT-288 resulted in cognitive improvement in clinically stable adults with schizophrenia.

show abstract

“…These 3 cognitive tasks have already been investigated in chronic schizophrenia and medicated first-episode (FE) schizophrenic patients. Poor performance on the RVIP has been revealed in chronic schizophrenia [13] , and in 11 medicated patients in the prodromal phase [14] . However, the small sample size, poor psychopathological characterization, and the comparison with a normative database of healthy volunteers are the constraints of the latter study.…”

Section: Introductionmentioning

confidence: 99%

Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Naïve First-Episode Schizophrenia Patients

Hilti¹,

Delko²,

Orosz³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Introduction: The nature of deficits in tests of sustained attention, planning and attentional set-shifting has not been investigated in neuroleptic-naïve first-episode (FE) schizophrenia patients. Based on previous literature of chronic and medicated FE schizophrenia patients, we predicted that the neuroleptic-naïve patients would show deficits in these cognitive processes. Methods: Twenty-nine neuroleptic-naïve FE schizophrenia patients and 33 healthy controls – matched by age, gender, and nicotine consumption – performed 3 tests from the Cambridge Automated Neuropsychological Test Battery (CANTAB) thought to measure these cognitive processes: the Rapid Visual Information Processing task (RVIP, sustained attention), the Stockings of Cambridge task (SOC, planning), and the Intradimensional/Extradimensional set-shifting task (IDED, attention shifting). Results: The patients were significantly impaired in the sensitivity index (A′) of the RVIP, and in the number of problems solved with minimum moves on the SOC. Nevertheless, the groups did not differ regarding the number of participants who failed at the crucial extradimensional shift stage of the IDED. Conclusion: Sustained attention and planning abilities are already impaired in neuroleptic-naïve FE schizophrenia patients, whereas set-shifting abilities as measured with the IDED task seem to be intact at illness onset. Since chronic schizophrenia patients have been shown to have impaired IDED performance, we tentatively propose that IDED performance deteriorates over time with illness chronicity and/or medication.

show abstract

Cognitive functions in prepsychotic patients

Cited by 60 publications

References 13 publications

Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis

Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Naïve First-Episode Schizophrenia Patients

Contact Info

Product

Resources

About